Stephan Rosenkranz
YOU?
Author Swipe
View article: VE/VCO2 at ventilatory threshold and peak VO2 in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses
VE/VCO2 at ventilatory threshold and peak VO2 in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses Open
The effect size of each meta-analysis indicates that higher VE/VCO2(VeT) and lower peak VO2 may be considered as independent CPET markers of PAH in patients with SSc. CPET is a non-invasive and safe procedure for expl…
View article: Exercise haemodynamics in pulmonary hypertension – a prospective pressure–volume loop study on right ventricular adaptation and prognosis
Exercise haemodynamics in pulmonary hypertension – a prospective pressure–volume loop study on right ventricular adaptation and prognosis Open
Aims The haemodynamic response to exercise is prognostic in pulmonary hypertension (PH). However, little is known about right ventricular (RV) adaptation in this context. We analysed the patterns and prognostic relevance of RV adaptation t…
View article: In-hospital cardiac arrest due to acute pulmonary embolism: a case report of successful catheter-directed thrombectomy on a patient with VA-ECMO
In-hospital cardiac arrest due to acute pulmonary embolism: a case report of successful catheter-directed thrombectomy on a patient with VA-ECMO Open
Background First-line therapy for high-risk pulmonary embolism (PE) is systemic thrombolysis. Catheter-directed thrombectomy (CDT) poses as a secondary option, primarily in patients with contraindications for systemic thrombolysis. However…
View article: Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysis
Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat <i>versus</i> other medications: a COMPERA analysis Open
View article: Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post‐ and Precapillary Pulmonary Hypertension: A Propensity Score‐Matched Analysis From the Hellenic Pulmonary Hypertension Registry
Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post‐ and Precapillary Pulmonary Hypertension: A Propensity Score‐Matched Analysis From the Hellenic Pulmonary Hypertension Registry Open
Combined post‐ and precapillary pulmonary hypertension (CpcPH) comprises the most severe form of postcapillary PH. A severe precapillary component (pulmonary vascular resistance [PVR] > 5 WU) is critical for therapeutic decisions. Current …
View article: Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis
Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis Open
Aims Pulmonary arterial hypertension (PAH) is often diagnosed in elderly patients with comorbidities. Although initial monotherapy is recommended for these patients, the value of combination therapy remains unclear. Here, we compare the ef…
View article: Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis Open
In Advancing Clinical Therapeutics Globally protocol A5372, a pharmacokinetic study of dolutegravir with 1-month of daily rifapentine/isoniazid, twice-daily dolutegravir offset the induction effects of rifapentine on plasma dolutegravir tr…
View article: MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial
MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial Open
View article: Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies
Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies Open
Background: Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure, often leading to right heart failure and poor prognosis. Depression, a common comorbidity in PH, significantly affects the quality of life. How…
View article: Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies Open
Introduction Pulmonary arterial hypertension is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the growth-pro…
View article: Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE
Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE Open
Aims Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF popula…
View article: Pulmonary Hypertension
Pulmonary Hypertension Open
View article: Dual-layer dual-energy CT characterization of thrombus composition in acute pulmonary embolism and chronic thromboembolic pulmonary hypertension
Dual-layer dual-energy CT characterization of thrombus composition in acute pulmonary embolism and chronic thromboembolic pulmonary hypertension Open
To evaluate dual-layer dual-energy computed tomography (dlDECT)-based characterization of thrombus composition for differentiation of acute pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH). This retrospecti…
View article: Structural and magnetic properties of CoTeMoO$_6$ revisited
Structural and magnetic properties of CoTeMoO$_6$ revisited Open
We have conducted a comprehensive investigation into the magnetic properties of the chiral multiferroic material CoTeMoO$_6$. In contrast with the previous claim of canted antiferromagnetic order with ferromagnetic components, our investig…
View article: Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies
Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies Open
In conclusion, this analysis supports the risk-reduction benefits of riociguat in patients with PAH at intermediate-low risk and intermediate-high risk, and externally validated the utility of COMPERA 2.0 in the long-term risk assessment o…
View article: Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities Open
This post hoc analysis suggests that patients with PAH and cardiovascular comorbidities can benefit from combination therapy with inhaled or oral treprostinil.
View article: Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration
Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration Open
Background Exercise pulmonary hypertension (exercise PH) was defined by a mean pulmonary arterial pressure (mPAP)/cardiac output (CO) slope >3 mmHg·L −1 ·min −1 between rest and exercise in the 2022 ESC/ERS PH guidelines. However, large, m…
View article: Phenotyping patients with chronic obstructive pulmonary disease and heart failure
Phenotyping patients with chronic obstructive pulmonary disease and heart failure Open
Aims Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are prevalent comorbidities associated with significant morbidity/mortality. We assessed prevalence of, patient profiles and outcomes associated with COPD across the …
View article: Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension
Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension Open
Summary Despite substantial advancements in the treatment of pulmonary arterial hypertension (PAH), obstacles remain in achieving optimal outcomes. In this study, we focus on understanding the therapeutic effect of targeting the ADORA1/PDE…
View article: Hematopoietic PI3Kδ deficiency aggravates murine atherosclerosis through impairment of Tregs
Hematopoietic PI3Kδ deficiency aggravates murine atherosclerosis through impairment of Tregs Open
Chronic activation of the adaptive immune system is a hallmark of atherosclerosis. As PI3Kδ is a key regulator of T and B cell differentiation and function, we hypothesized that alleviation of adaptive immunity by PI3Kδ inactivation may re…
View article: Prevalence and significance of pulmonary hypertension among hospitalized patients with left heart disease
Prevalence and significance of pulmonary hypertension among hospitalized patients with left heart disease Open
In a nationwide inpatient analysis the prevalence of PH-LHD was lower than previously reported indicating reduced recognition of this disease in real world clinical practice. The diagnosis of PH-LHD was associated with worse fatality rates…
View article: Inhibition of myeloperoxidase to treat left ventricular dysfunction in non‐ischaemic cardiomyopathy
Inhibition of myeloperoxidase to treat left ventricular dysfunction in non‐ischaemic cardiomyopathy Open
Aims Non‐ischaemic cardiomyopathy (NICMP), an incurable disease terminating in systolic heart failure (heart failure with reduced ejection fraction [HFrEF]), causes immune activation, however anti‐inflammatory treatment strategies so far h…
View article: Pulmonary hypertension in heart failure: the good, the bad, and the ugly
Pulmonary hypertension in heart failure: the good, the bad, and the ugly Open
Graphical AbstractClinical relevance of haemodynamic profiles in patients with heart failure and pulmonary hypertension. Based on the control of HF and within the pulmonary circulation, invasively measured cardiopulmonary haemodynamics may…
View article: Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities Open
Aims According to current guidelines, initial monotherapy should be considered for pulmonary arterial hypertension (PAH) patients with cardiopulmonary comorbidities. This analysis of combined data from the TRITON and REPAIR clinical trials…
View article: Air travel in patients suffering from pulmonary hypertension—A prospective, multicentre study
Air travel in patients suffering from pulmonary hypertension—A prospective, multicentre study Open
The PEGASUS study is the first multicentric and prospective assessment of the safety of air travel flying in pulmonary hypertension (PH) (NCT03051763). Data of air travel from 60 patients with PH was available. No severe adverse events occ…
View article: Comparison of different venous access ways for right heart catheterization—a meta-analysis
Comparison of different venous access ways for right heart catheterization—a meta-analysis Open
This meta-analysis showed that PVA for RHC has a significantly lower complication rate than CVA. There was a low level of certainty and high heterogeneity. This pooled data analysis indicated PVA as the primary venous access for RHC.
View article: Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study
Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study Open
Aims Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. We estimated, the chronic economic impact of PE on the German healthcare system. Methods and results We calculated the direct cost of illn…
View article: Right ventricular dysfunction and impaired right ventricular–pulmonary arterial coupling in paradoxical low‐flow, low‐gradient aortic stenosis
Right ventricular dysfunction and impaired right ventricular–pulmonary arterial coupling in paradoxical low‐flow, low‐gradient aortic stenosis Open
Aims Paradoxical low‐flow, low‐gradient aortic stenosis (pLFLG AS) may represent a diagnostic challenge, and its pathophysiology is complex. While left ventricular (LV) systolic function is preserved, right ventricular dysfunction (RVD) an…
View article: A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (<scp>HFA</scp>) of the <scp>ESC</scp> and the <scp>ESC</scp> Working Group on Pulmonary Circulation & Right Ventricular Function
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (<span>HFA</span>) of the <span>ESC</span> and the <span>ESC</span> Working Group on Pulmonary Circulation & Right Ventricular Function Open
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH‐LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimate…
View article: Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies Open
A blood test identifying patients at increased risk of pulmonary hypertension (PH) could streamline the investigative pathway. The prospective, multicenter CIPHER study aimed to develop a microRNA‐based signature for detecting PH in breath…